Stock info Ironwood Pharmaceuticals | Filter  Basic-Info

Ironwood Pharmaceuticals

The past year yielded positive returns for Ironwood Pharmaceuticals investors

The period between December 2015 and December 2016 was a good period for the investors. The stock gained almost 36 percent. Ironwood Pharmaceuticals' stock rose the past 5 years at around 40 percent. Ironwood Pharmaceuticals's revenues between 2011 and 2015 were quite similar and moved between 150,25 million dollars and 149,56 million dollars. Ironwood Pharmaceuticals's net results between 2011 and 2015 were far from constant and moved between -64,85 million dollars and -142,67 million dollars.

The company mostly operates in the biotech sector. The global biotech companies gained around 59 percent over the last 10 years. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

Ironwood Pharmaceuticals didn't pay out any dividends (in the past 5 years).

Ironwood Pharmaceuticals' balance mostly financed with equity

At the end of 2015 the biotech company's balance sheet equaled 619,12 million dollars. Last year the total debt of the company was 523,99 million dollars. This equals around 84,63 percent of the total balance sheet. The American company's price/earnings-ratio was -17. So the market valued the stock at -17 times the 2015' earnings per share. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the biotech company's market capitalization (the number of shares times the market price) equaled around 1,62 billion dollars. At the end of 2015 the American company had around 142,16 million stocks listed on the stock exchange(s).

All of Ironwood Pharmaceuticals's annual reports are stored here. More information about Ironwood Pharmaceuticals can be found it's website. .